-
'Don't have to hide': Thai IDs, legal work give hope to Myanmar refugees
-
Siemens shares plunge on disappointing guidance raise
-
Stocks mixed with tech firms back under pressure
-
New Australia coach Kiss gives Japan starts to Ross, Amatosero
-
How Blundell's old school tactic ended England's 'Bazball' era
-
'Stretch our money': Romanians face highest EU inflation
-
Israel reports troop deaths as Lebanon talks underway in Rome
-
Iran says close to Hormuz plan with Oman, but reopening depends on US
-
Seeds Rybakina, Pegula, Gauff reach third round at WTA Toronto
-
Messi scores twice to set Leagues Cup record in Miami victory
-
Police raid South Korea FA in probe into World Cup coach appointment
-
Asian stocks mostly down with tech firms back under pressure
-
Low water on Germany's Rhine river threatens new blow to economy
-
Back to the future as world champion Springboks host All Blacks
-
Ex-Wallabies Foley, Phipps rejoin Waratahs ahead of home World Cup
-
India youth protests highlight mistrust in 'lapdog' media
-
Rising Kenyan lakes push crocodiles closer to homes
-
Pacific islands alarmed by Trump-backed push for deep-sea mining
-
Istanbul cymbals: From Ottoman war tool to pulse of global music
-
Erratic rains dictate menu at three-star Michelin restaurant in Brazil
-
Myanmar ex-junta chief on first Thailand trip as civilian leader
-
Zverev, Auger-Aliassime and Medvedev exit Montreal Masters
-
Environmental disaster looms as tanker leaks off Oman
-
Google-parent Alphabet shakes up AI division
-
Embattled Infantino sees minnows Malawi reach WAFCON quarter-finals
-
FIFA back Infantino, apologise for World Cup privatisation plan
-
Seeds Rybakina, Pegula and Gauff advance at WTA Toronto event
-
Auger-Aliassime out of Montreal ATP event with injury
-
Zverev, Auger-Aliassime exit star-short Montreal Masters
-
Colombian baby hippo of Escobar stock dies after rescue
-
Embattled FIFA chief Infantino in emergency talks in Morocco
-
Preakness shifts 2027 dates to entice more Derby horses
-
Castaway SpaceX rocket stage crashed into Moon, scientists say
-
Guatemalan volcano eruption ends, locals return home
-
Dow edges to record as markets parse prospects for Hormuz deal
-
WHO chief urges stronger Ebola response in DR Congo visit
-
Salah arrives in Turkey to complete Trabzonspor move
-
Newcastle appoint Jaissle as new head coach after Howe exit
-
AFP journalist to be honored at International Press Freedom Awards
-
Swiss ski star Lara Gut-Behrami calls time on 18-year career
-
Turkish MPs back limited amnesty for Kurdish militants
-
US indicts leaders of Mexico's CJNG cartel, ups reward money
-
Noosha Aubel: Czy poradzi sobie z problemami Poczdamu?
-
Noosha Aubel: Είναι σε θέση να αντιμετωπίσει τα προβλήματα του Πότσδαμ;
-
Noosha Aubel: Klarar hon av Potsdams problem?
-
نوشا أوبيل: هل هي على مستوى التحديات التي تواجهها بوتسدام؟
-
Noosha Aubel: Zvládne problémy Postupimi?
-
Former England fly-half Burns retires from rugby union
-
Brazil hits new diplomatic lows with US and Argentina
-
Pakistan beat West Indies by eight wickets to level series
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Salvador--PC